388082-76-6 Usage
Description
5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride is a complex organic chemical compound characterized by the presence of a furan ring, a quinazoline ring, and chloro and fluorobenzyl groups. It also features an aldehyde functional group, which may contribute to its reactivity and potential applications in various fields. 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydroch is primarily utilized in pharmaceutical research, where its unique structure and properties could be harnessed for the development of novel therapeutic agents.
Uses
Used in Pharmaceutical Research:
5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride is used as a research compound for the development of new drugs. Its complex structure and functional groups may offer unique opportunities for medicinal chemists to explore its potential as a therapeutic agent, particularly in the treatment of various diseases and conditions.
Used in Drug Design and Synthesis:
In the pharmaceutical industry, 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride is used as a key intermediate in the synthesis of various drug candidates. Its unique structural features, including the furan and quinazoline rings, as well as the chloro and fluorobenzyl groups, can be exploited to design and synthesize novel compounds with potential therapeutic applications.
Used in Biological Assays and Screening:
5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride can be employed in biological assays and high-throughput screening processes to evaluate its potential biological activities and interactions with various biological targets. This information can be valuable in guiding further optimization and development of the compound as a drug candidate.
Used in Medicinal Chemistry Education:
As a complex and structurally interesting compound, 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride can be used as a teaching tool in medicinal chemistry courses and workshops. It can help students understand the importance of molecular structure in drug design and the role of various functional groups in modulating the biological activity of a compound.
Check Digit Verification of cas no
The CAS Registry Mumber 388082-76-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,8,8,0,8 and 2 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 388082-76:
(8*3)+(7*8)+(6*8)+(5*0)+(4*8)+(3*2)+(2*7)+(1*6)=186
186 % 10 = 6
So 388082-76-6 is a valid CAS Registry Number.
388082-76-6Relevant articles and documents
Method for synthesizing lapatinib or intermediate thereof
-
, (2017/06/30)
The invention relates to a method for synthesizing lapatinib or an intermediate thereof. The method for synthesizing the intermediate comprises the steps as follows: under the condition that a catalytic quantity of a catalyst exists in a solvent, 4-amino-5-(4-(3-chloro-4-(3-fluorobenzyloxy) phenylamino)-quinazoline reacts with furfural for preparation of 5-(4-(3-chloro-4-(3-fluorobenzyloxy) phenylamino)-quinazoline-6-yl)furyl-2-carboxaldehyde hydrochloride, and the intermediate is prepared. The invention further relates to a method for synthesizing lapatinib and/or salt of lapatinib, the intermediate of lapatinib and/or pharmaceutically acceptable salt of the intermediate, and the method is performed with the intermediate which is synthesized by the previous method. The method has the advantages that steps are simplified, a reagent is cheap, available and high in use ratio, pollution from heavy metal is avoided, and requirements for reaction conditions/operation are relatively low and/or the yield is high.
PROCESS AND INTERMEDIATES FOR PREPARING LAPATINIB
-
Page/Page column 15-16, (2011/10/13)
Provided are a process for preparing lapatinib and its pharmaceutically acceptable salt by use of new intermediates, and a process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate.
